 TG Therapeutics Incs NASDAQ: TGTX new data showed that ublituximab Ukoniq, dubbed U2, had an elevated risk of death in the phase 3 Unity combo trial or chronic lymphocytic leukemia CLL and small lymphocytic lymphoma SLL The data analyzed at the request of the FDA showed. 